Zacks Investment Research Lowers Dicerna Pharmaceuticals (NASDAQ:DRNA) to Sell
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
A number of other research firms also recently weighed in on DRNA. Royal Bank of Canada assumed coverage on Dicerna Pharmaceuticals in a research report on Tuesday, May 12th. They set an outperform rating and a $35.00 target price for the company. SVB Leerink upped their target price on Dicerna Pharmaceuticals from $35.00 to $38.00 and gave the company an outperform rating in a research report on Tuesday, April 7th. ValuEngine downgraded Dicerna Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, July 2nd. Chardan Capital reissued a buy rating and set a $25.00 price target on shares of Dicerna Pharmaceuticals in a report on Friday, May 8th. Finally, BidaskClub cut Dicerna Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $33.27.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.59). The business had revenue of $34.03 million for the quarter, compared to analyst estimates of $59.61 million. Dicerna Pharmaceuticals had a negative return on equity of 74.79% and a negative net margin of 213.04%. As a group, analysts anticipate that Dicerna Pharmaceuticals will post 0.18 EPS for the current fiscal year.
In related news, insider Bob D. Brown sold 8,185 shares of the company’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $21.00, for a total transaction of $171,885.00. Following the sale, the insider now owns 13,185 shares in the company, valued at approximately $276,885. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO James B. Weissman sold 4,360 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $20.20, for a total value of $88,072.00. Following the sale, the chief operating officer now owns 26,220 shares in the company, valued at approximately $529,644. The disclosure for this sale can be found here. In the last three months, insiders sold 60,586 shares of company stock valued at $1,416,813. Insiders own 11.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in DRNA. FDx Advisors Inc. bought a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at about $38,000. US Bancorp DE boosted its holdings in Dicerna Pharmaceuticals by 147.9% in the first quarter. US Bancorp DE now owns 2,975 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 1,775 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Dicerna Pharmaceuticals by 33.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,491 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 1,128 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in Dicerna Pharmaceuticals by 26.9% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,303 shares of the biopharmaceutical company’s stock worth $134,000 after acquiring an additional 1,547 shares in the last quarter. Finally, AJO LP bought a new position in Dicerna Pharmaceuticals in the first quarter worth approximately $174,000. Institutional investors own 82.77% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.